Stock PUR PURE BIOLOGICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Pure Biologics S.A. Share Price

Equities

PUR

PLPRBLG00010

Biotechnology & Medical Research

Delayed Warsaw S.E.
Other stock markets
 12:30:00 29/04/2024 pm IST 		5-day change 1st Jan Change
7.81 PLN 0.00% Intraday chart for Pure Biologics S.A. -1.76% -38.21%
2023 Pure Biologics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Pure Biologics S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Financials

Sales 2021 254K 63K 5.26M Sales 2022 662K 164K 13.7M Capitalization 51.84M 12.86M 1.07B
Net income 2021 -11M -2.73M -228M Net income 2022 -25M -6.2M -517M EV / Sales 2021 573 x
Net cash position 2021 29.82M 7.4M 617M Net cash position 2022 4.32M 1.07M 89.35M EV / Sales 2022 71.8 x
P/E ratio 2021
-14.7 x
P/E ratio 2022
-2 x
Employees 96
Yield 2021 *
-
Yield 2022
-
Free-Float 85.51%
More Fundamentals * Assessed data

Chart Pure Biologics S.A.

Dynamic Chart

Latest news about Pure Biologics S.A.

Pure Biologics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Pure Biologics S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Presage Announces Collaboration with Pure Biologics to Investigate Oncology Agents in Early Development with CIVO® Technology CI
Dom Maklerski Navigator S.A. and IPOPEMA Securities S.A. agreed to acquire an unknown minority stake in Pure Biologics Spólka Akcyjna. CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Pure Biologics Sp?lka Akcyjna Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Pure Biologics Spólka Akcyjna announced that it has received €6.7 million in funding from National Centre for Research and Development CI
Pure Biologics Spólka Akcyjna announced that it has received PLN 10.1 million in funding CI
More news

Quotes and Performance

1 week-1.76%
Current month-3.46%
1 month-2.98%
3 months-26.60%
6 months-37.52%
Current year-38.21%
More quotes

Highs and lows

1 week
7.76
Extreme 7.76
8.02
1 month
7.72
Extreme 7.72
8.49
Current year
6.95
Extreme 6.95
16.98
1 year
5.01
Extreme 5.01
21.90
3 years
5.01
Extreme 5.01
118.60
5 years
5.01
Extreme 5.01
152.00
10 years
5.01
Extreme 5.01
152.00
More quotes

Managers and Directors - Pure Biologics S.A.

Managers TitleAgeSince
Maciej Piotr Mazurek FOU
 Founder - 01/10/01
Filip Jan Jelen CEO
 Chief Executive Officer 47 01/10/01
Romuald Harwas DFI
 Director of Finance/CFO 52 16/19/16
Members of the board TitleAgeSince
Tadeusz Wesolowski BRD
 Director/Board Member 72 07/19/07
Andrzej Jan Trznadel FOU
 Founder 62 01/10/01
Pawel Marcin Wisniewski BRD
 Director/Board Member 44 26/23/26
More insiders

Quotes

Date Price Change Volume
29/24/29 7.81 0.00% 400
26/24/26 7.81 +0.64% 5,117
25/24/25 7.76 -0.51% 3,816
24/24/24 7.8 -1.89% 2,812
23/24/23 7.95 0.00% 5,352

Delayed Quote Warsaw S.E., April 29, 2024 at 12:30 pm IST

More quotes

Company Profile

Pure Biologics SA is a manufacturer of biological products. The Company was founded in August 2010 and is located in Wroclaw, Poland.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PURE BIOLOGICS S.A. Stock Pure Biologics S.A.
-38.21% 6.42M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+48.88% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PUR Stock